Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 7/20 | 0.45 |
| ▸ | HPGD | P15428 | 6/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.45 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.45 |
| ▸ | ABAT | P80404 | 1/20 | 0.45 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2962000 | 0.87 | FDPS (0.54) | FDPSALDH1A1KMT2AMAPTHPGD | |
| SCHEMBL378503 | 0.87 | FDPS (0.54) | FDPSALDH1A1KMT2AGAAKDM4E | |
| SCHEMBL3431684 | 0.85 | FDPS (0.56) | FDPSALDH1A1KMT2AKDM4EMAPT | |
| SCHEMBL27977829 | 0.84 | FDPS (0.64) | FDPSALDH1A1KMT2AGAAKDM4E | |
| SCHEMBL436111 | 0.83 | FDPS (0.54) | FDPSALDH1A1KMT2AMAPTHPGD | |
| SCHEMBL13212085 | 0.83 | FDPS (0.58) | FDPSALDH1A1KMT2AKDM4EMAPT | |
| SCHEMBL92184 | 0.82 | FDPS (0.81) | FDPSALDH1A1KMT2AGAAKDM4E | |
| SCHEMBL30694820 | 0.82 | FDPS (0.71) | FDPSALDH1A1KMT2AGAAKDM4E | |
| SCHEMBL29568186 | 0.82 | FDPS (0.81) | FDPSALDH1A1KMT2AGAAKDM4E | |
| SCHEMBL13230109 | 0.82 | FDPS (0.57) | FDPSALDH1A1KMT2AKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250097-A1 | BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF | Apollo Therapeutics Limited (GB) | 2023-08-10 | — | — | US | disclosed |
| US-8835457-B2 | Bridged bicyclic RHO kinase inhibitor compounds, compositions and use | MERCK SHARP & DOHME CORP. (US) | 2014-09-16 | — | — | US | disclosed |
| US-20130281485-A1 | BRIDGED BICYCLIC RHO KINASE INHIBITOR COMPOUNDS, COMPOSITIONS AND USE | MERCK SHARP & DOHME LLC | 2013-10-24 | — | — | US | disclosed |
| US-8476295-B2 | Bridged bicyclic RHO kinase inhibitor compounds, composition and use | Inspire (US) | 2013-07-02 | — | — | US | disclosed |
| EP-2595665-A1 | BIFUNCTIONAL RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | Inspire Pharmaceuticals, Inc. (US) | 2013-05-29 | — | — | EP | disclosed |
| US-20130131106-A1 | BIFUNCTIONAL RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | INSPIRE PHARMACEUTICALS, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| EP-2512239-A1 | BRIDGED BICYCLIC RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | Inspire Pharmaceuticals, Inc. (US) | 2012-10-24 | — | — | EP | disclosed |
| WO-2012012282-A1 | BIFUNCTIONAL RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | INSPIRE PHARMACEUTICALS, INC. (US) | 2012-01-26 | — | — | WO | disclosed |
| WO-2011075415-A1 | BRIDGED BICYCLIC RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | INSPIRE PHARMACEUTICALS, INC. (US) | 2011-06-23 | — | — | WO | disclosed |
| US-20110144150-A1 | BRIDGED BICYCLIC RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | MERCK SHARP & DOHME LLC | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250097-A1 | BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF | CSNK1A1, CSNK1D, CSNK2A1 | FDPS 4764/4885ALDH1A1 2913/4885KMT2A 740/4885 |
| US-20130281485-A1 | BRIDGED BICYCLIC RHO KINASE INHIBITOR COMPOUNDS, COMPOSITIONS AND USE | ROCK1, RHOA, ROCK2 | FDPS 2048/4885ALDH1A1 2703/4885KMT2A 3189/4885 |
| US-20110144150-A1 | BRIDGED BICYCLIC RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | ROCK1, RHOA, ROCK2 | FDPS 2072/4885ALDH1A1 2796/4885KMT2A 3262/4885 |
| US-20130131106-A1 | BIFUNCTIONAL RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | ROCK2, ROCK1, RHOA | FDPS 1092/4885ALDH1A1 4514/4885KMT2A 2348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.